Results 231 to 240 of about 262,914 (300)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

open access: yesMolecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary   +1 more
wiley   +1 more source

Manufacturing Supply Chains and Imports in the ADHD Drug Shortage.

open access: yesJAMA Health Forum
Currie J, Malinovskaya A.
europepmc   +1 more source

Durability of the insecticidal activity of next-generation insecticide treated nets distributed for malaria control in Mozambique: Findings from the New Nets Project (2020-2022). [PDF]

open access: yesPLOS Glob Public Health
Fagbohoun J   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy